TrakCel completes proof of concept phase for orchestration solution integration with UK NHS partners.

TrakCel completes proof of concept phase for orchestration solution integration with UK NHS partners.

Presented data confirms TrakCel-designed middleware can facilitate integration of orchestration software into pan-national healthcare IT systems

Cardiff, UK November 25, 2020 - TrakCel, the leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces it has completed Phase I of an integration of its technology with the UK’s Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC). The project is part of the development of the MW-ATTC initiative, which is funded by the Industrial Strategy Challenge Fund and Innovate UK, the UK’s public innovation agency, part of the United Kingdom Research and Innovation organization.

TrakCel assisted the University Hospitals Birmingham NHS Foundation Trust’s Health Informatics team with the development of orchestration-specific middleware, bridging software designed to manage the transfer of advanced therapy supply chain data between NHS IT systems and orchestration systems. The project has been defined as a critical step in developing the IT infrastructure necessary to simplify the management of advanced therapies by patient-facing healthcare professionals. 

The NHS partners of the MW-ATTC, as with other healthcare providers, use an assortment of IT and electronic systems at their various hospitals, trusts, and healthcare facilities. Without middleware, orchestration software would have to be individually integrated with each of those specific systems involving a high degree of complexity and cost. 

The MW-ATTC middleware project confirmed that the prototype NHS IT system would be able to integrate with multiple orchestration solutions, essential for the delivery of advanced therapies to NHS patients. Users would not require additional training on separate orchestration systems leading to financial and administrative savings to the NHS as it looks to streamline the delivery of commercialized advanced therapies to patients. 

TrakCel made the decision in 2018 to represent orchestration system suppliers by leading the development work of the NHS technology integration. As a result, TrakCel worked with different NHS teams to produce a detailed data exchange map critical for middleware development. This has ensured that TrakCel’s software will be able to exchange data with NHS’s systems. 

“Internationally, orchestration systems are a vital component to the delivery of advanced therapies. More cell and gene therapies and regenerative medicines are moving through commercialization and delivered to patients. As a result, healthcare systems around the world need to ensure safe and effective management of the complex processes involved in the global manufacture and delivery of these therapies,” said Dr Fiona Withey, CEO, TrakCel. 

“Demonstrating that bridging software can integrate orchestration software with the variety of existing IT systems and networks of a national healthcare provider such as the NHS is vital to ensure the management of therapies throughout the supply chain of cell and gene therapies. This ensures pan-industry standardization by enabling NHS professionals to continue to use familiar systems effectively integrated with orchestration systems to safely deliver therapies to patients,” Said Dr Matthew Lakelin, VP Business Development & Scientific Affairs.

 “We are delighted to be working in partnership with TrakCel on the Midlands and Wales Advanced Therapy Treatment project. We have been able to test the integration points on our prototype NHS IT ordering and scheduling system with a commercial partner, TrakCel. This is a step forward in making a standardized NHS IT system to facilitate ATMP treatments and a NHS IT system to link to cell orchestration platforms. This will allow ATMP treatments to become more mainstream,” said Professor Philip Newsome, Director of Midlands and Wales Advanced Therapy Treatment Centre, University of Birmingham.

About TrakCel 

TrakCel is the market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability.  TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. 

https://trakcel.com

About MW-ATTC

The 9 Million Pound  Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC) is one of three national Innovate UK funded centres whose goal is to accelerate the delivery of advanced therapies.

It is a regional network spanning the Midlands & Wales comprising a large consortium of industry, healthcare and university partners with expertise in advanced therapy manufacturing including academic and commercial partners, logistics companies, specialists in clinical trial delivery and teams focussed on IT logistics solutions and health economics.

The aim of the MW-ATTC is to enable UK advanced therapy companies to reach the clinical market, whilst simultaneously building clinical capacity regionally to deliver these breakthrough therapies to patients.

https://www.theattcnetwork.co.uk/centres/midlands-wales